Related Experiment Video
Updated: Jun 5, 2025

Author Spotlight: Impact of Intergenic Interactions on Disease-Identifying Dark Biomarkers
Published on: March 1, 2024
Model Complexity Reduction for ZKML Healthcare Applications: Privacy Protection and Inference Optimization for ZKML
Sathya Krishnasamy1, Ilangovan Govindarajan2
1President and Principal, ChainAim, Newington, Connecticut, USA.
Abstract:
Web 3.0 represents the next significant evolution of the internet that embodies the underlying decentralized network architectures, distributed ledgers, and advanced AI capabilities. Though the technologies are maturing rapidly, considerable barriers exist to high-scale adoption. The author discusses the barriers and the mitigations through specific technologies maturing to solve those issues in an earlier paper titled Moving Beyond POCs and Pilots, published in 2023 in Blockchain in Healthcare Today. These include privacy-preserving technologies, off-chain and on-chain design optimizations, and the multi-dimensional approach needed in planning and adopting these technologies. As an extension, this paper discusses one such enabler, zero knowledge machine learning (ZKML), which merges two streams of technology in unique ways to address problems in privacy and the cost of inference. Zero-knowledge proofs (ZKP) allow one party to prove the validity of a statement to another party without revealing any additional information about the statement itself. The ZKML combines the cryptographic principle of ZKP with machine learning (ML) techniques. It is still a maturing technology and needs baselines for applications in global healthcare. In this effort, the authors conceptualize the technical and operational feasibility of using ZKML and implement a reference healthcare implementation using the synthetic International Consortium for Health Outcomes Measurement (ICHOM) in the evaluation phase in a global healthcare setting for high-volume data collection, including patient-reported outcomes. Model complexity reduction is researched and reported for the ICHOM diabetes dataset to advance the usage of ML models in global standards of healthcare data collection in network decentralized architectures for increased data protection and efficiencies.
More Related Videos
07:50A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts
Published on: September 20, 2018
09:15Creation of Patient-Specific Silicone Cardiac Models with Applications in Pre-surgical Plans and Hands-on Training
Published on: February 10, 2022
Related Concept Videos
Multicompartment Models: Overview
These models offer a more comprehensive representation of drug behavior in the body than one-compartment models. They accommodate the complexity of drug distribution,...
Model Approaches for Pharmacokinetic Data: Compartment Models
Two primary types of compartment models are recognized: mammillary and catenary. The more...
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
One-Compartment Open Model: Wagner-Nelson and Loo Riegelman Method for ka Estimation
On...
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...